We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Collagen Solutions Plc | LSE:COS | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.625 | 6.25 | 7.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCOS
RNS Number : 7870V
Collagen Solutions PLC
25 July 2018
25 July 2018
Collagen Solutions plc
("Collagen Solutions" or the "Company")
Posting of Annual Report and Notice of AGM
Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, confirms that the Annual Report and Accounts for the year ended 31 March 2018 ('2018 Annual Report and Accounts'), the Notice of Annual General Meeting ('AGM') and a Form of Proxy will be posted to shareholders on 26 July 2018. A copy of the 2018 Annual Report and Accounts will be available to download from the Company website from that date.
The AGM will be held at 11.00am on 22 August 2018 at 3 Robroyston Oval, Nova Business Park, Glasgow G33 1AP.
For additional information on Collagen Solutions, please visit: www.collagensolutions.com
Collagen Solutions Plc Jamal Rushdy, CEO Via Walbrook Hilary Spence, CFO Lisa Baderoon, Investor Mob: 07721 413 496 or lisa.baderoon@collagensolutions.com Relations Cenkos Securities Plc (Nominated Adviser and Broker) Steve Cox (Corporate Finance) Tel: 0207 397 8900 Stephen Keys Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: 07876 741 001 Helen Cresswell Mob: 07841 917 679
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCPGUMGMUPRGQA
(END) Dow Jones Newswires
July 25, 2018 12:21 ET (16:21 GMT)
1 Year Collagen Solutions Chart |
1 Month Collagen Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions